Mitochondrial encephalomyopathy and lactic acidosis with strokelike episodes (MELAS) is a severe young onset stroke disorder without effective treatment. We have identified a MELAS patient harboring a 13528A3 G mitochondrial DNA (mtDNA) mutation in the Complex I ND5 gene. This mutation was homoplasmic in mtDNA from patient muscle and nearly homoplasmic (99.9%) in blood. Fibroblasts from the patient exhibited decreased mitochondrial membrane potential (⌬ m ) and increased lactate production, consistent with impaired mitochondrial function. Transfer of patient mtDNA to a new nuclear background using transmitochondrial cybrid fusions confirmed the pathogenicity of the 13528A3 G mutation; Complex I-linked respiration and ⌬ m were both significantly reduced in patient mtDNA cybrids compared with controls. Inhibition of the adenine nucleotide translocase or the F 1 F 0 -ATPase with bongkrekic acid or oligomycin caused a loss of potential in patient mtDNA cybrid mitochondria, indicating a requirement for glycolytically generated ATP to maintain ⌬ m . This was confirmed by inhibition of glycolysis with 2-deoxy-Dglucose, which caused depletion of ATP and mitochondrial depolarization in patient mtDNA cybrids. These data suggest that in response to impaired respiration due to the mtDNA mutation, mitochondria consume ATP to maintain ⌬ m , representing a potential pathophysiological mechanism in human mitochondrial disease.
Mitochondrial encephalomyopathy and lactic acidosis with strokelike episodes (MELAS) is a severe young onset stroke disorder without effective treatment. We have identified a MELAS patient harboring a 13528A3 G mitochondrial DNA (mtDNA) mutation in the Complex I ND5 gene. This mutation was homoplasmic in mtDNA from patient muscle and nearly homoplasmic (99.9%) in blood. Fibroblasts from the patient exhibited decreased mitochondrial membrane potential (⌬ m ) and increased lactate production, consistent with impaired mitochondrial function. Transfer of patient mtDNA to a new nuclear background using transmitochondrial cybrid fusions confirmed the pathogenicity of the 13528A3 G mutation; Complex I-linked respiration and ⌬ m were both significantly reduced in patient mtDNA cybrids compared with controls. Inhibition of the adenine nucleotide translocase or the F 1 F 0 -ATPase with bongkrekic acid or oligomycin caused a loss of potential in patient mtDNA cybrid mitochondria, indicating a requirement for glycolytically generated ATP to maintain ⌬ m . This was confirmed by inhibition of glycolysis with 2-deoxy-Dglucose, which caused depletion of ATP and mitochondrial depolarization in patient mtDNA cybrids. These data suggest that in response to impaired respiration due to the mtDNA mutation, mitochondria consume ATP to maintain ⌬ m , representing a potential pathophysiological mechanism in human mitochondrial disease.
Mitochondrial respiration is fundamental to the well being of most mammalian cells, since it provides the central mechanism that couples fuel and oxygen consumption to ATP synthesis. The mitochondrial respiratory chain resides at the inner membrane and consists of five multimeric enzyme complexes: I (NADH:ubiquinone oxidoreductase), II (succinate:ubiquinone oxidoreductase), III (ubiquinol:cytochrome c oxidoreductase), IV (cytochrome c oxidase), and V (F 1 F 0 -ATPase). Electrons donated from the tricarboxylic acid cycle to Complexes I and II are utilized by Complexes I, III, and IV to pump protons from the matrix to the intermembrane space. The resulting electrochemical potential gradient, normally expressed as a mitochondrial membrane potential (⌬ m ), 2 provides the energy to drive ATP synthesis by Complex V (1, 2) .
Mitochondria contain their own unique, double-stranded, circular genome, which encodes the 13 essential protein subunits of the respiratory complexes. It also encodes the 12 and 16 S rRNAs and the 22 tRNAs specific for mitochondrial protein synthesis. Mutations in mitochondrial DNA (mtDNA) are associated with a wide variety of multisystemic degenerative diseases (3) . Aspects of central nervous system and muscle function are usually affected, whereas a number of mutations are also variably associated with deafness, diabetes, and optic nerve atrophy or retinal degeneration (2, 4) . In many cases, the pathogenic mtDNA mutation associated with the respiratory defect has been assigned, but it is still unclear why different mtDNA mutations result in such a wide array of clinical phenotypes.
Mitochondrial encephalomyopathy and lactic acidosis with strokelike episodes (MELAS) is a young onset mitochondrial disease that often occurs in childhood with gradual deterioration. The disease commonly presents with strokes, hypertrophic cardiomyopathy, dementia and/or seizures, lactic acidosis, and myopathy (5) . Genetically defined cases of MELAS most commonly associate with heteroplasmic mtDNA mutations in the tRNA leucine (UUR) gene (6) ; however, the mitochondrial ND5 gene may also represent a hotspot for MELAScausing mutations (7) (8) (9) . Transmitochondrial cybrids generated from MELAS patient mitochondria that harbor the 3243A3 G tRNA leucine mutation exhibit significant biochemical abnormalities, including defects of Complex I (10 -12) . Reduced ATP synthesis (13), decreased ⌬ m (14) , and * This work was supported by the Wellcome Trust and Medical Research Council. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact. mitochondrial calcium buffering defects (15) have also been described in MELAS patient fibroblasts.
Here we describe a patient with maternally inherited MELAS who harbors a homoplasmic mtDNA mutation in the ND5 gene on the mtDNA haplogroup U. Fibroblasts from the patient exhibited deficiencies in mitochondrial function in the form of increased lactate production and decreased ⌬ m . These defects were transferred when transmitochondrial cybrids were generated with the patient's mtDNA, confirming the pathogenicity of the ND5 gene mutation. Unexpectedly, we found that mitochondria harboring the ND5 mutation consumed cytosolic ATP to maintain ⌬ m . Such mitochondrial ATP consumption due to a mtDNA mutation has not been reported previously and may represent an important component of the cellular pathophysiology in patients with MELAS or other mitochondrial diseases.
EXPERIMENTAL PROCEDURES
Case Report-The subject (referred to as Patient 1) presented with severe strokelike episodes and epilepsy in early adolescence. She did not have diabetes, ophthalmoplegia, or cardiomyopathy. At age 24, she experienced episodes of seizures followed by visual impairment and headaches. A CT scan showed right occipital infarction. She developed epilepsia partialis continua with dystonic movements affecting her left arm. Anticonvulsants and transpial resection brain surgery were not successful. She has myopathic muscle weakness, peripheral neuropathy, and hearing impairment. Muscle biopsy showed cytochrome c oxidase-negative ragged red fibers, suggesting mitochondrial disease.
Real Time Quantitative PCR Experiments-DNA was extracted from peripheral blood lymphocytes or from muscle biopsies using standard procedures. All samples were normalized to a set concentration (50 ng/l) prior to experimentation. Two Assay-on-Demand SNP genotyping products were designed at the ND5 13528 and 13565 variants termed ND5_1 and ND5_2, respectively (primer and probe sequences are available on request). The manufacturer's protocols were followed for the preparation of the TaqMan assays, all assays were run on an ABI PRISM 7500 sequence detection system, and results were analyzed using sequence detection system software (SDS 2.0). All reactions were normalized using an 18 S rRNA endogenous control. For target quantification, Ct data obtained from real time PCR was adjusted by the 2 Ϫ⌬⌬Ct method (16). Therefore, prior to the utilization of the technique, we ensured that amplification efficiencies of the ND5_1 and 18 S rRNA probes were similar across a serial dilution of 5 logs by plotting the resulting ⌬Ct against the log of the input amount. The slope of the linear regression line was 0.08, indicating that the two probes were well matched for DNA concentration-dependant amplification efficiency.
PCR and Restriction Fragment Length Polymorphism Analysis for Quantification of the Proportion of the Mutant mtDNA-
The presence of the 13528A3 G mutation (T398A) was confirmed by PCR amplification, followed by Fnu4HI restriction enzyme digestion. The oligonucleotide primers were 13301-13320 for the light strand and 13841-13822 for the heavy strand. In the presence of the mutant nucleotide "C", Fnu4HI cleaves the 541-bp amplified product into four fragments of 65, 132, 164, and 180 bp.
A mismatch PCR was designed to screen for the 13565C3 T mutation (S410F), in which a restriction site for MseI was introduced in the presence of T at position 13,565. The oligonucleotide primers were 13,385-13,405 for the light strand and 13,582-13,565, AGGTAGCGATGAGAGTAATT (mismatch nucleotide in boldface and underlined type) for the heavy strand. In the presence of a mutant nucleotide, the 198-bp fragment was cleaved into two fragments, 180 and 18 bp. All fragments were separated by agarose gel (3.2%) electrophoresis and were visualized with ethidium bromide staining using a UV trans-illuminator.
Preparation of Primary Cell Cultures and of Human Mitochondrial Cybrids-Human mitochondrial cybrids were produced by enucleation of mitochondrial donor cells and fusion of the cytoplasts with human 143B osteosarcoma 0 cells followed by selection for respiratory competent transformants (17) . Cells used as mitochondrial donors included two different control fibroblast cell lines (designated FC1 and FC2) and a fibroblast cell line derived form the MELAS patient (designated FP1).
Briefly, around 2 ϫ 10 6 cells were harvested and resuspended in sterile 50-ml polysulfone centrifuge tubes (Nalge, Rochester, NY) in a mixture of 10 ml of RPMI 1640 medium (Invitrogen) supplemented with 10% (w/v) fetal bovine serum (Invitrogen), 4.5 mg/ml glucose, 50 g/ml uridine, and 1 mM pyruvate (RPMI/GUP), 10 ml of Percoll (Amersham Biosciences), 1ϫ penicillin/streptomycin, and 20 g/ml cytochalasin B (from a 2 mg/ml stock in Me 2 SO). Cells were centrifuged at 19,000 rpm (44,000 ϫ g av ) for 70 min at 37°C, and the cytoplast/karyoplast mixture was collected from the medium/Percoll interface. The mixture was diluted in 15 ml of RPMI/GUP and centrifuged at 1000 ϫ g for 3 min to remove excess Percoll before being combined with 5 ϫ 10 5 human 143B 0 cells (mtDNA-less) and centrifuged at 10,000 ϫ g for 10 min. The supernatant was removed by aspiration, and the pellet was overlaid with polyethylene glycol for 1 min. The polyethylene glycol was then removed, and the cells were gently resuspended and plated at 0.5 ϫ 10 5 , 1 ϫ 10 5 , and 2 ϫ 10 5 cells/100-mm dish in RPMI/ GUP medium. After 24 h, the medium was replaced with select medium: RPMI supplemented with 5% (w/v) dialyzed fetal bovine serum (Invitrogen), 4.5 mg/ml glucose, and 50 g/ml bromodeoxyuridine. After ϳ14 days, cybrid clones were isolated using cloning cylinders, expanded, and viably frozen.
Growth Assays-Growth assays were performed in Dulbecco's modified Eagle's medium supplemented with either 4.5 g/liter glucose or galactose. Galactose cannot be used efficiently in glycolytic pathways, and therefore cells rely predominantly on oxidative phosphorylation to produce ATP. Counting of the number of cells was accomplished with a Beckman Coulter particle counter.
Oxygen Respiratory Activity-To measure respiration rate in intact cells ϳ1 ϫ 10 7 cells were suspended in respiration medium (5.37 mM KCl, 0.44 mM KH 2 PO 4 , 4.17 mM NaHCO 3 , 137 mM NaCl, 0.34 mM Na 2 HPO 4 , pH 7.2) with 5.6 mM D-glucose in a Clark-type oxygen electrode thermostatically maintained at 37°C. Oxygen consumption was measured over 10 min with additions of oligomycin (final concentration 5 g/ml) and carbonyl cyanide p-trifluoromethoxyphenylhydrazone (FCCP; 100 nM). To measure respiration rate in digitonin-permeabilized cells, ϳ1 ϫ 10 7 cells were harvested and resuspended in intracellular medium (135 mM KCl, 10 mM NaCl, 20 mM HEPES, 0.5 mM KH 2 PO 4 , 1 mM MgCl 2 , 5 mM EGTA, 1.86 mM CaCl 2 , pH 7.1) with 50 g/ml digitonin. Oxygen consumption was measured in a Clark-type oxygen electrode thermostatically maintained at 37°C. Glutamate (5 mM) and malate (5 mM) were added to measure Complex I-linked respiration, succinate (5 mM) with rotenone (5 g/ml) were added to measure Complex II-linked respiration. All data were obtained using a MacLab system with Chart recording software. The oxygen electrode was calibrated with air-saturated water, assuming 406 nmol of oxygen atoms/ml at 37°C.
Lactic Acid Assay-Lactate was measured by growing cells in RPMI/GUP medium at 37°C/5% CO 2 for up to 48 h. Aliquots of medium were removed at various time intervals and incubated with 0.2 M glycine/hydrazine, pH 9.2, 33 units/ml lactate dehydrogenase, and 3.3 mg/ml NAD at 37°C for 30 min before spectrophotometric determination of NAD reduction at 340 nm. Measurements were performed in triplicate and standardized per cell.
ATP Measurements-ATP levels were measured using the ATP bioluminescence assay kit HS II (Roche Applied Science) according to the manufacturer's instructions. Briefly, cells were incubated for 2 h in record solution (156 mM NaCl, 3 mM KCl, 2 mM MgSO 4 , 1.25 mM KH 2 PO 4 , 2 mM CaCl 2 , 20 mM HEPES, pH 7.35) with either 10 mM glucose, 10 mM glucose plus 2.5 g/ml oligomycin (glycolytic ATP generation), or 5 mM 2-deoxy-Dglucose plus 5 mM pyruvate (oxidative ATP production). Cells were lysed with the solutions provided, and lysates were incubated with the luciferin/luciferase reagents. Samples were measured using a PerkinElmer Life Sciences microplate luminometer.
Fluorescent Imaging of Cells-All cells were loaded with fluorescent dyes in buffer containing 156 mM NaCl, 3 mM KCl, 2 mM MgSO 4 , 1.25 mM KH 2 PO 4 , 10 mM D-glucose, 2 mM CaCl 2 , 10 mM HEPES, pH 7.35 (record solution).
For measurements of the free cytosolic Mg 2ϩ concentration [Mg 2ϩ ] c as an index of ATP hydrolysis (since ATP has a higher affinity than ADP for Mg 2ϩ ), the Mg 2ϩ sensitive dye Magnesium Green (5 g/ml; Molecular Probes) (K d ϭ 1 mM) was used (18) . This dye has a low affinity for Ca 2ϩ (K d ϭ 6 M); therefore, experiments were performed in conjunction with Fura-2/AM (5 g/ml; Molecular Probes; K d ϭ 140 nM for Ca 2ϩ ) to monitor [Ca 2ϩ ] c in parallel. Fluorescent images were captured on a Nikon epifluorescence inverted microscope with a ϫ40 objective. A xenon arc lamp with 10-nm band pass filters centered at 340 nm, 380 nm (for Fura-2/AM), and 490 nm (for Magnesium Green) was used for excitation (Cairn Research, Kent, UK), with emitted light passing through a 515-nm long pass filter to an interline transfer cooled CCD camera (Orca ER; Hamamatsu). Images were digitized to 12-bit and analyzed using Kinetic Imaging software (Liverpool, UK). ⌬ m was measured by incubating cells in high potassium record solution (as described previously but with 109 mM NaCl, 50 mM KCl, in order to avoid contributions from differences in the plasma membrane potential) with 20 nM tetramethylrhodamine methyl ester (TMRM; Molecular Probes) and 10 M verapamil (which is required to inhibit TMRM export from the cell on the multidrug transporter). Cells were allowed to equilibrate the dye for at least 45 min at room temperature before confocal imaging. Additions of 10 M bongkrekic acid, 2 mM cyanide (CN Ϫ ), 2.5 g/ml oligomycin, 20 M sodium azide (NaN 3 ), 5 mM 2-deoxy-D-glucose, or 10 M FCCP were made as indicated. ⌬ m measurements were made by acquiring images with a Carl Zeiss 510 inverted laser-scanning confocal microscope (Oberkochen, Germany). TMRM was excited using a 543-nm helium-neon laser with resulting images analyzed using Carl Zeiss Kinetic Imaging TM or Metamorph TM software. The mean intensity of the TMRM signal per pixel was measured over mitochondrial structures only and therefore was independent of mitochondrial mass or density.
RESULTS
mtDNA Analysis-Large scale deletions of mtDNA were excluded in the proband muscle by long PCR and by Southern blotting. We screened the entire mitochondrial genome by automated sequencing analysis and identified three previously unreported silent nucleotide changes in the MELAS patient (Patient 1) (9389A3 G, 11340T3 C, 15373A3 G) and two homoplasmic missense mutations at positions 13528A3 G and 13565C3 T. The first missense mutation results in a threonine to alanine substitution at position 398 (T398A) and has been reported to be associated with Leber hereditary optic neuropathy (LHON) (19) . The 13565C3 T mutation results in a serine to phenylalanine substitution (S410F) at a highly conserved position in the ND5 protein. Sequencing of the D-loop region showed that the mtDNA from Patient 1 was from the haplogroup U with the two mutations absent in 192 sequenced control samples. We note that there is one report of this combination of mutations on haplogroup U (20). Real time quantitative PCR analysis was performed on DNA extracted from muscle and blood from Patient 1 and also blood from the patient's mother. The 13565C3 T mutation was homoplasmic in muscle (Patient 1) and blood (both Patient 1 and mother). The 13528A3 G mutation was also homoplasmic in DNA from Patient 1 muscle, but small amounts of wild-type mtDNA were detected at position 13,528 in blood from both Patient 1 (0.001%, range 0.0007-0.0017%) and the patient's mother (6.1%, range 5.8 -6.4%). The proportions given are relative quantifications based on a very robust real time assay; the average Ct values at 13,528 in the blood of Patient 1 were well within the detectable range at 32.563 (S.E. ϭ 0.697) compared with control at 15.1 (S.E. ϭ 0.032). To validate the quantification of the wild-type allele of the 13,528 variant, the probe was initially validated in nine control samples across a 5 log dilution; we were therefore able to amplify the wild-type allele from a concentration of 0.005 ng/l. The results of the allelic variance experiments were also validated against the 13,565 probe which was homoplasmic in both blood and muscle from both patients. (Fig. 1A) . During anaerobic metabolism, oxidized NADH (which is rate-limiting for glycolysis) is generated by the reduction of pyruvate to lactate. Lactate generation was 2 times greater in Patient 1 fibroblasts (FP1) over a period of 48 h compared with control fibroblasts (FC1 and FC2), suggesting an increased requirement for glycolytic metabolism due to mitochondrial dysfunction (Fig. 1B) .
Functional Analysis of Patient 1 Mitochondria-Despite
To assess whether these defects were associated with the mtDNA, transmitochondrial cybrid cells were created by fusing fibroblast mitochondria from Patient 1 with 143B 0 mtDNA-depleted osteosarcoma cells. Homoplasmic transmission of Patient 1 mtDNA to the new cybrid fusion was confirmed by restriction fragment length polymorphism analysis (data not shown). Two control cybrids containing wild-type mtDNA from different fibroblast cultures were also generated.
There was no growth impairment of Patient 1 cybrid cells (P1) compared with control cybrids (C1 and C2), with growth rates the same in both glucose and galactose ( Fig. 2A) . 143B 0 cells, with no oxidative ATP production, grew poorly in both glucose and galactose ( Fig. 2A) . However, in a similar fashion to Patient 1 fibroblasts, ⌬ m in Patient 1 cybrids (P1) was also significantly reduced to 72% (p Ͻ 0.05) compared with control cybrids (C1 and C2) (Fig. 2B) . Lactate generation over 48 h in Patient 1 cybrids (P1) was also significantly greater than in control cybrids (C1 and C2) (Fig. 2C) .
The rate of oxygen consumption in Patient 1 cybrid cells was also significantly lower, with a respiratory rate at only 44% (p Ͻ (Table 1) . Respiratory rates were significantly depressed by oligomycin in the two control cybrids (C1 and C2) but not in Patient 1 cybrids, whereas FCCP increased respiratory rates ϳ2.4-fold in the control cybrids (C1 and C2) but only ϳ1.25-fold in Patient 1 cybrids (Table 1) . In digitonin-permeabilized cells, Complex I-linked respiration (rotenone-sensitive) was only 37% (p Ͻ 0.05) in Patient 1 cybrids compared with controls ( Table 2 ). The respiratory control ratio, being the ratio of state III (ADP excess)/state IV (ADP limited) respiration, was also lower in Patient 1 cybrids, indicating a decreased capacity for generating ATP above basal levels (Table 2) . Complex II-linked respiration in Patient 1 cybrids was not significantly different from controls (p ϭ 0.23), indicating that the respiratory defect is associated with Complex I (Table 3) .
0.05) when measured in intact cells
Maintenance of ⌬ m in Patient 1 Cybrids Requires Import of ATP-⌬ m was examined in the control cybrid (C1), the Patient 1 cybrid (P1), and 143B 0 cells after inhibiting the adenine nucleotide translocator (ANT) and F 1 F 0 -ATPase (Fig. 3) . In the control cybrid (C1), inhibition of the ANT with bongkrekic acid increased ⌬ m (as measured by an increase in TMRM fluorescence). This effect is attributable to the inhibition of the electrogenic activity of the ANT and the subsequent inhibition of the F 1 F 0 -ATPase following a rise in intramitochondrial ATP concentration (Fig. 3A) . In 0 cells, the opposite was observed, with the collapse of ⌬ m following ANT blockade (Fig. 3A) . In this case, ⌬ m is dependent on the "reverse" function of the ANT, which imports glycolytic ATP 4Ϫ in exchange for ADP 3Ϫ . This provides an outward current to generate ⌬ m and a supply of ATP for hydrolysis by the 
TABLE 3 Complex II-linked respiration in permeabilized cells
Oxygen consumption was measured in digitonin-permeabilized cells with the Complex II-linked substrate succinate (5 mM, with 5 g/ml rotenone). Results are mean Ϯ S.D. from three independent experiments/cell line. g ϩ m, 5 mM glutamate plus 5 mM malate; RCR, respiratory control ratio. (Fig. 3A) , suggesting that ⌬ m in Patient 1 mutant mitochondria is maintained in a similar fashion to 0 cells by reversal of the ANT.
Cell line Oxygen atoms (g ؉ m) RCR ng/min/mg
Oligomycin, which inhibits the F 0 component of the F 1 F 0 -ATPase, increased ⌬ m in the control cybrid (C1) as the H ϩ flux through F 0 into the mitochondrial matrix was blocked (Fig.  3B) . Conversely, oligomycin caused ⌬ m to collapse in Patient 1 cybrids (P1), suggesting that the F 1 F 0 -ATPase was functioning in reverse to maintain ⌬ m (Fig. 3B) . In 0 cells, oligomycin had no effect on ⌬ m due to the lack of the mtDNA-encoded oligomycin-sensitive ATP6 subunit in these cells (22) . As proof of principle, a control cell line was exposed to a low concentration of rotenone to inhibit Complex I. No change in ⌬ m was seen until the addition of oligomycin, showing that ⌬ m can be effectively maintained by the ATPase following inhibition of Complex I (supplemental Fig. 1) .
Sodium azide treatment increased ⌬ m in the control cybrid (C1) by inhibiting the F 1 component of the ATPase (Fig. 3C) . Azide can also inhibit cytochrome c oxidase (Complex IV) of the respiratory chain and depolarize mitochondria but did not do so at the concentrations used here (20 M). In both the Patient 1 cybrids (P1) and 0 cells, F 1 -ATPase inhibition by sodium azide resulted in the loss of ⌬ m (Fig. 3C) .
ATP Is Generated Glycolytically in Patient 1 Mutant Mitochondria-The capacity of Patient 1 mutant mitochondria to support oxidative phosphorylation was examined by measuring cellular [ATP] using a luciferin/luciferase assay. Populations of cells were cultured with glucose (G) or under conditions that supported only glycolytic (glucose with oligomycin, G ϩ O) or mitochondrial (2-deoxy-D-glucose with pyruvate, D ϩ P) ATP synthesis (Fig. 4A) . The control cybrids (C1 and C2), the Patient 1 cybrid (P1), and 0 cells all maintained similar resting levels of ATP under glycolytic conditions (Fig. 4A, G ϩ O) . However, under oxidative conditions in the presence of 2-deoxy-D-glucose and pyruvate (D ϩ P), ATP levels were significantly reduced in Patient 1 cybrids (P1) to only 60% (p Ͻ 0.05) of control values (Fig. 4A) . ATP levels were also dramatically reduced in 0 cells to 9% when glycolysis was inhibited (D ϩ P), which would be expected for these respiratory deficient cells (Fig. 4A) . to decrease after an ϳ10-min incubation with 2-deoxy-D-glucose, with the rate of hydrolysis reaching a maximum after ϳ20 min (Fig. 4B) . In 143B 0 cells, a decrease in cellular [ATP] occurred after only ϳ5 min, with hydrolysis proceeding at a faster rate than in Patient 1 cybrids (Fig. 4B) . ⌬ m was unaffected in the control cybrid (C1) during 2-deoxy-D-glucose incubation (Fig. 4C) , since the intact respiratory chain in these cells utilizes oxidative substrates to generate a ⌬ m . However, in Patient 1 cybrids (P1), mitochondrial depolarization began ϳ25 min after 2-deoxy-D-glucose treatment (Fig. 4C) , indicating that glycolytically generated ATP is required to maintain a ⌬ m in these cells. 143B 0 cells (with no respiratory capacity) also depolarized after inhibiting glycolytic ATP generation with 2-deoxy-D-glucose, in this case after only ϳ10 min of incubation (Fig. 4C) .
Inhibition of Glycolytic ATP Generation Results in Depolar-

DISCUSSION
We have identified a patient with the mitochondrial disease MELAS who harbors two missense mutations at positions 13,528 and 13,565 in the mitochondrial ND5 gene. Both mutations were homoplasmic (or near homoplasmic) in the patient's muscle and blood. The patient's mother was found to be homoplasmic for the 13565C3 T mutation but heteroplasmic for the 13528A3 G mutation, with 6% wild-type mtDNA at this position. The 13,528 and 13,565 changes have been described previously on haplogroup U in the apparent absence of a disease phenotype (20) ; however, the 13528A3 G mutation has been reported in association with Leber hereditary optic neuropathy (LHON) (19) . No other nonsilent mtDNA changes were identified, suggesting that these two mtDNA mutations contribute to the disease phenotype in the MELAS patient. Although harboring the same mutations, the mother was asymptomatic at the age of 65 years. The difference in mtDNA load of the 13528A3 G mutation may underlie the difference in phenotype between the severely affected proband and her clinically normal mother. This would suggest a very high expression threshold for this mutation. Alternatively, both the 13528A3 G mutation and the homoplasmic 13565C3 T mutation are pathogenic, but nuclear genetic factors may compensate for the mitochondrial defect in the mother. Such variable penetrance in the presence of a homoplasmic mtDNA mutation has not been described previously in MELAS but is recognized in other mitochondrial diseases, such as LHON (23) and neonatal/infantile fatality (24) . Recent evidence also suggests that an X-chromosomal haplotype influences disease penetrance in LHON (25) .
To confirm that the 13528A3 G and 13565C3 T mutations are pathogenic in the MELAS patient, we created transmitochondrial cybrids with the patient's mtDNA. Reduced ⌬ m and increased lactate production were observed in both the patient's primary fibroblasts (homoplasmic for both mutations) and the cybrids generated with the patient's mitochondria, confirming the association of the mitochondrial disease with the mutations in the patient's mtDNA. Measurements of oxygen consumption with Complex I and Complex II-linked substrates revealed a Complex I deficiency, and uncoupling the respiratory chain from the ATPase revealed minimal functional reserve. It is noteworthy that although oxygen consumption measurements revealed a Complex I deficiency, no Complex I enzymatic defect (NADH dehydrogenase activity) was detected in the muscle biopsy from the patient. Similar observations have been reported in cybrid studies of Complex I mtDNA mutations (11778G3 A and 14484T3 C) associated with LHON but not for MELAS (26, 27) . This suggests that the primary consequence of the mtDNA mutations in the patient is not a reduction in NADH dehydrogenase activity but possibly a deficiency in proton pumping across the inner mitochondrial membrane. This proposal is supported by the observed reduction in ⌬ m in both patient fibroblasts and cybrids and also the position of the 13565C3 T and 13528A3 G mutations in the hydrophobic membrane-bound ND5 subunit.
Surprisingly, we observed that the patient's mitochondria maintain ⌬ m by ATP consumption. This is a logical consequence of the thermodynamic principles that govern mitochondrial function and has been described previously when respiratory chain activity is either chemically inhibited (28) or absent altogether (21) . However, mitochondrial ATP consumption has not been previously reported in association with a human disease causing mtDNA mutation. The equilibrium of the F 1 F 0 -ATPase is a function of the free energy of the phosphorylation potential (ATP/ADP⅐P i ) and of the electrochemical potential for protons. Given a decreased ⌬ m, with impaired respiration and a favorable phosphorylation potential through glycolytic ATP supply, the enzyme operates as a proton-translocating ATPase. This happens under many pathological states (e.g. during anoxia (29) or following uncoupling (30) ). However, our observations suggest that this behavior can occur in response to the impaired respiratory activity resulting from point mutations in the Complex I subunit ND5 gene. The same principle would be expected to apply in other mtDNA diseases in which mitochondrial respiration is impaired. The point is illustrated in supplemental Fig. 1 , which shows that ⌬ m was maintained in cells following partial inhibition of Complex I by a low concentration of rotenone until the addition of oligomycin, which then caused an abrupt loss of potential. Thus, the potential was maintained by reversal of the ATP synthase during inhibition of Complex I.
To our knowledge, there has been no real discussion in the literature of this mode of pathogenesis resulting from mtDNA mutations. In myofibers from collagen VI-deficient (Col6a1 Ϫ/Ϫ ) mice, ATPase activity seemed to maintain ⌬ m in the face of PTP opening rather than a respiratory defect (31) . It has also been suggested that in cells containing mtDNA mutations, the equilibration of ATP in mitochondria and cytosol is due to mitochondrial ATP import from the cytoplasm (32) . It seems inevitable that mitochondrial ATP consumption in intact tissues in the human subject will result in energetic failure of the tissue under a variety of conditions, particularly when dependent on glycolytic activity, ATP consumption by other processes, and local oxygen supply.
These findings lead to a number of simple and testable predictions that may explain puzzling aspects of mitochondrial genetic disease. Thus, proliferation of mutant mitochondria seen in "ragged red" fibers is predicted to be harmful and increase the metabolic burden on the cell rather than overcom-ing the defect, so mitochondrial proliferation may represent a mechanism that dictates the severity of clinical symptoms in a way that might seem counterintuitive. Furthermore, although the rate of ATP consumption required to maintain ⌬ m may be very low in many cells under most conditions, it may be increased dramatically by any process that slows respiration further (e.g. inhibition by hypoxia or NO) or by any leakiness of mitochondrial membranes (e.g. due to an up-regulation of uncoupling proteins). Such transient events could explain the occurrence of occasional crises, such as stroke-like episodes, seen in MELAS patients. We suggest that the conceptual framework provided here may lead to new therapies for such patients, especially noting the development of novel drugs that selectively reduce ATP hydrolysis by the mitochondrial F 1 F oATPase (33) .
